Search Result

Isoforms Recommended:	PARP12

Results for "

PARP12

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PARP (27) Apoptosis (3) CDK (1) Isotope-Labeled Compounds (2) Microtubule/Tubulin (2) Poly(ADP-ribose) Glycohydrolase (PARG) (1) PROTACs (1) Reference Standards (1) Small Interfering RNA (siRNA) (3) Wnt (3) β-catenin (3)
By Research Areas:	Cancer (27) Inflammation/Immunology (2) Neurological Disease (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: PARP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16106

Talazoparib Maximum Cited Publications 98 Publications Verification BMN-673; LT-673	PARP	Cancer
Talazoparib (BMN-673) is a highly potent, orally active *PARP1/2* inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .

HY-137450

Senaparib IMP4297; JS109	PARP	Cancer
Senaparib (IMP4297) is a highly potent, selective and orally active *PARP1/2* inhibitor. Senaparib (IMP4297) exhibits strong antitumor activity in animal models .

HY-148566

OUL232 2 Publications Verification	PARP	Cancer
OUL232 is a potent inhibitor of mono-ARTs PARP7, PARP10, PARP11, PARP12, PARP14, and *PARP15. OUL232 is the most potent PARP10* inhibitor described to date (IC₅₀=7.8 nM), as well as the first *PARP12* inhibitor ever reported .

HY-108413

Talazoparib tosylate Maximum Cited Publications 98 Publications Verification BMN 673ts	PARP	Cancer
Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available *PARP1/2* inhibitor with an IC₅₀ of 0.57 nM for PARP1.

HY-13688

PJ34 hydrochloride 30+ Cited Publications	PARP	Cancer
PJ34 hydrochloride is an inhibitor of *PARP1/2* with IC₅₀ of 110 nM and 86 nM, respectively.

HY-145584

Nesuparib JPI-547/OCN-201	PARP Wnt β-catenin	Neurological Disease Cancer
Nesuparib (JPI-547) is the orally active inhibitor for *PARP 1/2* and Tankyrase 1/2 that inhibits tankyrases 1, tankyrases 2, and PARP 1 with IC₅₀s of 5, 1 and 2 nM, respectively. Nesuparib exhibits antitumor activity and can be used in research of advanced solid tumor .

HY-133531

PDD00017272	Poly(ADP-ribose) Glycohydrolase (PARG)	Cancer
PDD00017272 is an inhibitor of poly(ADP-ribose) glycohydrolase (PARG) (EC₅₀=4.8 nM) and an activator of *PARP1/2. PDD00017272 inhibits its activity of hydrolyzing poly(ADP-ribose) (pADPr), resulting in the accumulation of pADPr* on chromatin, interfering with DNA damage repair and replication processes, and inducing *PARP1/2*-dependent cytotoxicity. PDD00017272 can be used in cancer models with DNA repair defects (such as BRCA mutations) or resistance to PARP inhibitors. PDD00017272 has a PARG expression level-correlated inhibitory potency with EC₅₀ of 9.2 nM (PARG cells), the tumor cells with lower PARG expression are more sensitive .

HY-145734

AMXI-5001	Microtubule/Tubulin	Cancer
AMXI-5001 is a potent, orally active, and dual *parp1/2* and microtubule polymerization inhibitor. MXI-5001 exhibits selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC₅₀s than existing clinical PARP1/2 inhibitors. AMXI-5001 induces complete regression of established tumors, including exceedingly large tumors .

HY-122661

Mefuparib hydrochloride MPH	PARP Apoptosis	Cancer
Mefuparib hydrochloride (MPH) is an orally active, substrate-competitive and selective *PARP1/2* inhibitor with IC₅₀s of 3.2 nM and 1.9 nM, respectively. Mefuparib hydrochloride induces apoptosis and possesses prominent anticancer activity in vitro and in vivo .

HY-115552

Simmiparib	PARP	Cancer
Simmiparib is a highly potent and orally active *PARP1* and *PARP2* inhibitor with IC₅₀ values of 1.75 nM and 0.22 nM, respectively. Simmiparib has more potent PARP1/2 inhibition than its parent Olaparib (HY-10162). Simmiparib induces DNA double-strand breaks (DSB) accumulation and G2/M arrest in homologous recombination repair (HR)-deficient cells, thereby inducing apoptosis. Simmiparib exhibits remarkable anticancer activities in cells and nude mice bearing xenografts .

HY-RS19519

Parp12 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Parp12 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp12 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Parp12 Mouse Pre-designed siRNA Set A Parp12 Mouse Pre-designed siRNA Set A

HY-155993

YCH1899	PARP	Cancer
YCH1899 is an orally active *PARP* inhibitor, with an IC₅₀< 0.001 nM for PARP1/2. YCH1899 exhibits distinct antiproliferation activity against Olaparib (HY-10162)-resistant and Talazoparib (HY-16106)-resistant Capan-1 cells (Capan-1/OP and Capan-1/TP cells) , with IC₅₀ values of 0.89 and 1.13 nM, respectively. YCH1899 has acceptable pharmacokinetic properties in rats .

HY-RS10054

PARP12 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PARP12 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PARP12 Human Pre-designed siRNA Set A PARP12 Human Pre-designed siRNA Set A

HY-16106S1

Talazoparib-d4 BMN-673-d₄; LT-673-d₄	Isotope-Labeled Compounds PARP	Cancer
Talazoparib-d₄ (BMN-673-d₄) is deuterium labeled Talazoparib. Talazoparib (BMN-673) is a highly potent, orally active *PARP1/2* inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .

HY-16106S

Talazoparib-13C,d4 BMN-673-¹³C,d₄; LT-673-¹³C,d₄	Isotope-Labeled Compounds	Others
Talazoparib- ¹³C,d4 is ¹³C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.

HY-146336

PARP1/2/TNKS1/2-IN-1	PARP Apoptosis Wnt β-catenin	Cancer
PARP1/2/TNKS1/2-IN-1 is a potent and selective dual *PARP-1/2* and *TNKS1/2* inhibitor with IC₅₀ values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM for PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 suppresses Wnt/β-catenin signaling, decreases pADPr and BRCA1 expression, induces DNA damage, promotes apoptosis, and arrests the cell cycle at the G2/M phase. PARP1/2/TNKS1/2-IN-1 can be used for the study of on colorectal cancer and triple-negative breast cancer .

HY-RS26014

Parp12 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Parp12 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp12 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Parp12 Rat Pre-designed siRNA Set A Parp12 Rat Pre-designed siRNA Set A

HY-168657

PARP1/2-IN-4	PARP	Others
PARP1/2-IN-4 (compound 3) is a *PARP1/2* inhibitor .

HY-145328

PARP-1/2-IN-1	PARP	Others
PARP-1/2-IN-1 is a potent PARP-1/2 inhibitor with IC₅₀ of 0.51 nM and 23.11 nM, respectively.

HY-145734A

AMXI-5001 hydrochloride	Microtubule/Tubulin	Cancer
AMXI-5001 hydrochloride is a potent, orally active, and dual *parp1/2* and microtubule polymerization inhibitor. MXI-5001 hydrochloride exhibits selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC₅₀s than existing clinical PARP1/2 inhibitors. AMXI-5001 hydrochloride induces complete regression of established tumors, including exceedingly large tumors .

HY-13688R

PJ34 hydrochloride (Standard)	PARP	Cancer
PJ34 (hydrochloride) (Standard) is the analytical standard of PJ34 (hydrochloride). This product is intended for research and analytical applications. PJ34 hydrochloride is an inhibitor of PARP1/2 with IC50 of 110 nM and 86 nM, respectively.

HY-137450A

Senaparib hydrochloride IMP4297 hydrochloride; JS109 hydrochloride	PARP	Cancer
Senaparib hydrochloride (IMP4297 hydrochloride) is an oral, selective PARP1/2 inhibitor with potent anti-tumor activity. Senaparib hydrochloride shows antitumor activity against advanced ovarian cancer .

HY-149398

PARP-1/2-IN-2	Apoptosis PARP CDK	Cancer
PARP-1/2-IN-2-IN-1 (Compound 12e) is a *PARP1/2/CDK12* inhibitor (IC₅₀: 34, 30 and 285 nM respectively). PARP-1/2-IN-2 inhibits DNA damage repair, promotes cell cycle arrest and apoptosis. PARP-1/2-IN-2 inhibits the growth of TNBC cells and TNBC xenograft tumor .

HY-171543

PARP1-IN-37	PARP	Cancer
PARP1-IN-37 (Compound 8) is an orally active and selective poly(ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitor with an IC₅₀ value of 24 nM for PARP1. PARP1-IN-37 inhibits PARP activity in cells with an EC₅₀ value of 3.7 μM. PARP1-IN-37 is promising for research of BRCA-mutated tumors, such as breast and ovarian cancers .

HY-155458

HYDAMTIQ	PARP	Inflammation/Immunology Cancer
HYDAMTIQ is a PARP-1/2 inhibitor (IC₅₀: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits pulmonary PARP activity, is effective against allergen-induced cough and dyspnea, and inhibits bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancers, prostate and pancreatic tumors, and glioblastoma multiforme. HYDAMTIQ has demonstrated in vivo efficacy in animal models of cerebral ischemia, asthma, cancer, and more .

HY-14687

(rac)-Talazoparib (rac)-BMN-673; (rac)-LT-673	PARP	Cancer
(rac)-Talazoparib ((rac)-BMN-673) (Compound 47) is the orally active inhibitor for *PARP1/2* with K_i of 1.2 nM and 0.87 nM. (rac)-Talazoparib inhibits cellular PARylation with an EC₅₀ of 2.51 nM. (rac)-Talazoparib causes the accumulation of DNA damage, inhibits proliferation of BRCA1/2-mutated MX-1 cell and Capan-1 cell with IC₅₀ of 0.3 nM and 5 nM. (rac)-Talazoparib exhibits antitumor efficacy in mouse models .

HY-172747

TNKS-2-IN-3	PARP	Cancer
TNKS-2-IN-3 (Compound 5) is a selective competitive tankyrase 2 (TNKS2) inhibitor with an IC₅₀ value of 0.3 nM, showing over 20-fold selectivity over TNKS1 and more than 100-fold selectivity over PARP1/2. TNKS-2-IN-3 stabilizes axin and suppresses the Wnt/β-catenin pathway by inhibiting TNKS2-mediated ADP-ribosylation, exhibiting antiproliferative activity in colorectal cancer cells. TNKS-2-IN-3 is proming for rasearch of solid tumors with aberrant Wnt pathway activation, such as colorectal cancer .

HY-179349

PARP-1/2-IN-5	PARP	Neurological Disease Inflammation/Immunology
PARP-1/2-IN-5 (Compound 12) is a *PARP-1/2* inhibitor, with the IC₅₀ values for PARP-1 and PARP-2 being 118 and 11 nM respectively. PARP-1/2-IN-5 can be used for the study of inflammatory diseases and neurodegenerative disorders .

HY-108413R

Talazoparib tosylate (Standard) BMN 673ts (Standard)	Reference Standards PARP	Cancer
Talazoparib tosylate (Standard) is the analytical standard of Talazoparib tosylate (HY-108413). This product is intended for research and analytical applications. Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available PARP1/2 inhibitor with an IC₅₀ of 0.57 nM for PARP1.

HY-163817

PARP1/2-IN-3	PARP	Cancer
PARP1/2-IN-3 (Compound 29) is an orally active inhibitor for PARP 1 and PARP 2 with IC₅₀ of 0.2235 nM and <0.001 nM. PARP1/2-IN-3 inhibits the proliferation of Capan-1 wildtype, AZD2281 or BMN673 resistant cells with IC₅₀ of 1.82-9.98 nM. PARP1/2-IN-3 exhibits antitumor efficacy in mice .

HY-162172

PARP7-IN-18	PARP	Cancer
PARP7-IN-18 is a potent, highly selective, and orally active *PARP7* inhibitor with an IC₅₀ of 0.11 nM. PARP7-IN-18 exhibits >1000-fold selectivity over other PARP family members. PARP7-IN-18 inhibits NCI-H1373 lung cancer cell proliferation with an IC₅₀ of 2.5 nM and promotes IFN-β expression. PARP7-IN-18 exhibits favorable pharmacokinetic properties and can be used in research on PARP7-sensitive tumors, such as lung cancer .

HY-130646

iVeliparib-AP6	PROTACs PARP	Cancer
iVeliparib-AP6 is a proteolysis-targeting chimera (PROTAC) molecule designed based on Veliparib (HY-10129), which targets *PARP1/2. The DC₅₀s* of iVeliparib-AP6 for inducing the degradation of PARP1 and PARP2 are 36 nM and 63 nM, respectively, and its IC₅₀s are 69 nM and 21 nM, respectively. iVeliparib-AP6 contains a Veliparib-based PARP inhibitor warhead linked to a CRBN E3 ligase binder; it uses Thalidomide (HY-14658) as a ligand to recruit CRBN E3 ubiquitin ligase and exerts the PARP2 degradation mechanism .

HY-180809

YCH3292	PARP	Cancer
YCH3292, a derivative of YCH189 (HY-155993) is a potent, selective and orally active *PARP1/2* inhibitor with IC₅₀ both <0.001 nM. YCH3292 can increase the stability of PARP-DNA complexes. YCH3292 exhibits robust antiproliferative activity. YCH3292 can induce double-strand breaks in DNA, increase the protein levels of γH2AX, P-RPA32, and P-Chk1 and induce tumor cells S or G2/M phase arrest and apoptosis. YCH3292 can inhibit tumor growth in MC38 xenograft model .

HY-145584A

Nesuparib hydrochloride JPI-547/OCN-201 hydrochloride	PARP Wnt β-catenin	Cancer
Nesuparib (JPI-547) hydrochloride is the orally active inhibitor for *PARP 1/2* and Tankyrase 1/2 that inhibits tankyrases 1, tankyrases 2, and PARP 1 with IC₅₀s of 5, 1 and 2 nM, respectively. Nesuparib hydrochloride exhibits antitumor activity and can be used in research of advanced solid tumor .

Cat. No.	Product Name	Chemical Structure

HY-16106S1

Talazoparib-d4
Talazoparib-d₄ (BMN-673-d₄) is deuterium labeled Talazoparib. Talazoparib (BMN-673) is a highly potent, orally active *PARP1/2* inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .

HY-16106S

Talazoparib-13C,d4
Talazoparib- ¹³C,d4 is ¹³C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.

Parp12 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Parp12 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp12 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

PARP12 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PARP12 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Parp12 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Parp12 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp12 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: